Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42165279 in Social Anxiety Disorder
NCT02432703Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of JNJ-42165279 in Social Anxiety Disorder (SAD), sponsored by Janssen Pharmaceutical. Started Jun 2015; status: completed.
02
Drugs
JNJ-42165279
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT02432703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432703.